Director Declaration

02 Dec 2003

| Filed in:

The following information is provided in compliance with paragraph 16.4 of the FSA Listing Rules in respect of the appointments of Dr David Fish and Mr Evert Henkes as Non-Executive Directors of Tate & Lyle PLC on 1 December 2003 (as announced on 5 November 2003). Dr David Fish i) Dr Fish is currently a director and Chairman of Christian Salvesen PLC (appointed a director on 21 October 2002). He holds no directorships in any other publicly quoted companies and has not done so in the last five years. ii) There are no details to disclose under paragraph 6.F.2(b) to (g) of the Listing Rules in relation to Dr Fish. iii) At the date of his appointment, Dr Fish had an interest over 11,750 ordinary shares in Tate & Lyle PLC. He had no interest in any options over ordinary shares in Tate & Lyle PLC. Mr Evert Henkes i) Mr Henkes is currently a director of BPB PLC (appointed a director on 1 August 2003) and Outokumpu OYJ (appointed a director on 3 April 2003) which is a company listed on the Helsinki Stock Exchange. He holds no directorships in any other publicly quoted companies and has not done so in the last five years. ii) There are no details to disclose under paragraph 6.F.2(b) to (g) of the Listing Rules in relation to Mr Henkes. iii) At the date of his appointment, Mr Henkes had no interest in ordinary shares or options in Tate & Lyle PLC.
Robert Gibber
Company Secretary
Tate & Lyle PLC

Click here for our press image gallery

About Tate & Lyle PLC:

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

Through our leading expertise in sweetening, mouthfeel and fortiﬁcation, we develop ingredients and solutions which reduce sugar, calories and fat, add ﬁbre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 39 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate & Lyle Group would have been £2.25 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedIn, X (Twitter), Facebook or YouTube

Previous press release Holding(s) in Company

View all Press releases

Next press release Holding(s) in Company